Uncategorized

Ipsen scuttles liver disease candidates from $952M Albireo acquisition

Published

on

Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version